Piramal Pharma Ltd Italy India United Kingdom

Piramal Pharma Limited Announces Results for Q4 and FY2025

Click Here

 

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

* Includes one facility via PPL's minority investment in Yapan Bio.

For more information, visit:  Piramal Pharma | LinkedIn

Logo - https://mma.prnewswire.com/media/1855206/4913155/Piramal_Pharma_Limited_Logo.jpg

 

 

                      

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-results-for-q4-and-fy2025-302455718.html